Partner 3 Trial Results
Data from the Partner 3 trial affirms the effectiveness of Transcatheter Aortic Valve Replacement (TAVR) compared to Surgical Aortic Valve Replacement (SAVR), even in low-risk patients.
Stakeholders have long wondered if TAVR devices could match the durability of their surgically implanted counterparts. However, seven-year data from the trial shows no statistically significant difference in outcomes such as mortality and morbidity.
Patients, physicians, payers, and regulators need not fret about device durability.
The topline numbers suggest that TAVR is a viable option for low-risk patients, providing similar results to SAVR.
Author's summary: TAVR matches SAVR in low-risk patients.